

## 2020 HFSA Annual Scientific Meeting: CE

### Course Details and Faculty Listing

<b>COVID-19: Lessons Learned in Heart Failure and Living with the New Normal</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Acute COVID-19 Cardiovascular Syndrome	N. Hendren; Internal Medicine, University of Texas-Southwestern, Dallas, TX.
RAAS Inhibitor Therapies and Other Core HF Therapies in Heart Failure (during the pandemic and when COVID-19 Positive)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Social Distancing, Social Isolation and Heart Failure: Lessons Learned in Regard to Self-Care	B. Davidson; Association of American Heart Failure Nurses, Nashville, TN.
Telemedicine in COVID-19- Strengths, Limitations and Innovations Needed	M. Vaduganathan; Brigham and Women's Hospital Heart and Vascular Ce, Boston, MA.
Moderator (Panel Q&A)	N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.
Panel Discussion	
<b>To Right A Wrong in Heart Failure</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Saltzberg; Medical College of Wisconsin, Milwaukee, WI.
Pathophysiology and Differential Diagnosis of Right Ventricular Dysfunction	M. Jacob; Cleveland Clinic, Cleveland, OH.
Assessment of Right Ventricular Function	R. J. Tedford; Medical University of South Carolina, Charleston, SC.
Medical Optimization of Right Ventricular in HFrEF and HFpEF	P. Shah; Inova Heart and Vascular Institute, Falls Church, VA.
Device Management in Right Ventricular Failure	N. K. Kapur; Tufts Medical Center, Boston, MA.
Moderator (Panel / Q&A)	M. Crespo-Leiro; University Hospital A Coruna, A Coruna Galicia, SPAIN.
Case Study & Panel Discussion	
<b>Clinical Conundrums - Multidisciplinary Case Discussion</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator	J. Howlett; University of Calgary, Calgary, AB, CANADA.
Moderator	J. Wilcox; Northwestern University Feinberg School of Medicine, Chicago, IL.
Clinical Conundrums (Multidisciplinary Case Discussion)	P. Mather; Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
Clinical Conundrums (Multidisciplinary Case Discussion)	B. Davidson; American Association of Heart Failure Nurses, Nashville, TN.
Clinical Conundrums (Multidisciplinary Case Discussion)	R. J. D. DiDomenico; University of Illinois at Chicago, Chicago, IL.
Clinical Conundrums (Multidisciplinary Case Discussion)	S. Keteyian; Henry Ford Health System, Detroit, MI.
<b>Beyond Socioeconomic &amp; Access to Care: The Clinical Imperative for Understanding Racial HF Differences and Disparities</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	A. A. Morris; Cardiology, Emory University, Atlanta, GA.
Racial Differences In Rates of Heart Failure Hospitalization and Death: A Growing Problem	B. Ziaei; David Geffen School of Medicine at UCLA, Los Angeles, CA.
Not Just a Man's Disease: The Disproportionate Burden of Heart Failure in Women of Color	E. Hsieh; Cleveland Clinic, Cleveland, OH.
Genetic Determinants that Contribute to the Higher Incidence of Heart Failure in Persons of African Ancestry	D. M. McNamara, Sr.; University of Pittsburgh Medical Center, Pittsburgh, PA.
A-HeFT or A-LEFT Behind? Disparities in the Medical Management of HFREF in Black Patients	E. Lewis; Stanford University Medical Center, Stanford, CA.
Moderator (Panel / Q&A)	C. Yancy; Northwestern University Feinberg School of Medicine, Chicago, IL.
Panelist	K. Breathett; University of Arizona, Tucson, AZ.
Panelist	C. J. Rodriguez; Albert Einstein College of Medicine, Bronx, NY.
Case Study & Panel Discussion	
<b>Heart Meets Kidney</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. A. Brisco-Bacik; Temple Health & Vascular Institute, Philadelphia, PA.
Latest Insights to Pathophysiology of CRS	H. H. Chen; Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Diuretic Decongestion Strategies: Which DOSE, Route and Combination?	A. Bagnola; Inova Heart and Vascular Institute, Falls Church, VA.
Cardio-Renal Learnings From New Trials	J. P. Dwyer; Vanderbilt University Medical Center, Nashville, TN.
Non-Medication Based Therapeutic Strategies	J. M. Testani; Yale University, New Haven, CT.
Moderator (Panel / Q&A)	P. McCullough; Baylor Heart & Vascular Hospital, Dallas, TX.
Case Study & Panel Discussion	
<b>Future HF Trials</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator	M. Konstam; Tufts Medical Center, Boston, MA.
Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure	J. R. Teerlink; Cardiology, 111C, San Francisco VAMC/UCSF, San Francisco, CA.
AHF Studies with SGLT2 Inhibitors	Z. Cox; Vanderbilt University Medical Center, Nashville, TN.
Post-MI studies with SGLT2 inhibitors	J. A. Udell; Cardiology/Medicine, Women's College Hospital, Toronto, ON, CANADA.
IV Iron Replacement Outcomes Trials	R. J. Mentz; Medicine, Cardiology, Duke University Medical Center, Durham, NC.
PARADISE-MI	E. Lewis; Stanford University Medical Center, Stanford, CA.
<b>Excellence in Translational Science: Fast Track Discovery to Application</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Preamble and Objectives	P. Liu; University of Ottawa Heart Institute, Ottawa Canada, ON.
Technologies to Fast Track Translation - Single Cell Omics for Personalized Medicine	M. Snyder; Stanford University School of Medicine, Palo Alto, CA.
Technologies to Fast Track Translation - Big Data/AI Deep Modeling of Molecular Interactions	F. Lightstone; Lawrence Livermore/AHA Collaborative Initiative, Livermore, CA.
Technologies to Fast Track Translation - Power and Pitfalls of AI Applied to ECHO	C. Lam; National Heart Centre, Singapore/Duke-NUS Medical School, Singapore, SINGAPORE.
"Tom Force" Keynote Lecture: Myosin Myopathies: Pathogenesis and Potential Therapeutics	L. Leinwand; Howard Hughes Medical Institute, Boulder, CO.
Panel Discussion	Panel Moderators: Walter Koch, Joseph Wu, Discussants: Michael Snyder, Felice Lightstone, Carolyn Lam, Leslie Leinwand, Wilson Tang, Howard Rockman
Progress from Bench to Bedside and Insights Learned - Myosin Inhibitors (Mayacamten in HCM)	M. Semigran; MyoKardia, Brisbane, CA.
Progress from Bench to Bedside and Insights Learned - Myosin Activators	F. I. Malik; Cytokinetics, San Francisco, CA.
Progress from Bench to Bedside and Insights Learned - SPECIAL LECTURE: Limitations of Infarct Size - the Open Artery Hypothesis	E. Braunwald; Harvard Medical School, Brigham and Women's Hospital, Boston, MA.
Bedside to Bench Reverse Translation - SGLT2i in HF and Role of Autophagy	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Bedside to Bench Reverse Translation - What COVID-19 has Taught Us About Translation	D. Mann; Washington University School of Medicine, St. Louis, MO.
Facilitating Translational Acceleration - NIH/NCATS Small Business Program	L. Portilla; National Institutes of Health, Bethesda, MD.
Facilitating Translational Acceleration - AHA	I. Benjamin; American Heart Association/Froedtert& Medical College of Wisconsin, Dallas, TX.
Facilitating Translational Acceleration - JMP	G. Singh; JMP Securities, San Francisco, CA.
Facilitating Translational Acceleration - FDA - Device -21	B. Zuckerman; Food and Drug Administration, Bethesda, MD.

Panel Moderators: Mariell Jessup, Joseph Hill, Discussants: Douglas Mann, Lili Portilla, Ivor Benjamin, Eric Rose, Gobind Singh, Bram Zuckerman	
<b>Update on Medical Treatment Strategies in HF</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
How to Sequence New Therapies in HF	G. Fonarow; University of California Los Angeles, Los Angeles, CA.
Benefits of Comprehensive Medical Treatment	M. Vaduganathan; Brigham and Women's Hospital Heart and Vascular Center, Boston, MA.
How to Individualize Medical Treatment - One Size Does not Fit All	M. Nassif; Saint Lukes Mid America Heart Institute, Kansas City, MO.
<b>Supporting the HF Workforce: Optimizing Physical and Mental Wellness Among HF Providers</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	A. Moore Gibbs; Atrium Health - Sanger Heart & Vascular Institute, Charlotte, NC.
Clinician Well-Being A Healthy Policy Perspective	T. Shanafelt; Stanford Medicine - WellMD Center, Stanford, CA.
How to Identify and Act on Early Signs of Clinician Burnout	C. Sinsky; Sinsky Healthcare Innovations, Philadelphia, PA.
Tips for Healthy Living at Work: Staying Active and Eating Healthy	R. Arena; University of Illinois at Chicago, College of Applied Health Sciences, Chicago, IL.
Burnout and Quality of Work Life Among Cardiology Practitioners	J. Casida; Johns Hopkins University, Baltimore, MD.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Physician)	P. Harris; American Medical Association, Washington, DC.
Role of Professional Societies in Support and Protecting HF Clinicians Against Burnout (Nurse)	C. Lewis; Vanderbilt University Medical Center, Nashville, TN.
<b>HF and the End of Life - Opportunities for Innovation and Collaboration at the Intersection of Cardiology and Palliative Care</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	A. O'Donnell; Department of Cardiology, Boston University School of Social Work, Boston, MA.
Role of Early Palliative Care for Heart Failure: Planning Ahead without Creating Much Ado about Nothing	S. Chuzi; Northwestern University, Chicago, IL.
Advanced Therapies and Palliative Care: Big Decisions, Big Considerations, Big Feelings	H. Warraich; Brigham and Women's Hospital/Boston Veterans Affairs Medical Center, Boston, MA.
Innovative Partnerships Between Palliative Care and Heart Failure Cardiology: Creating a Team of Teams	K. R. Dobbie; Palliative Medicine, Cleveland Clinic, Cleveland, OH.
Social Determinants and Financial Considerations at End of Life: In Hospice You Can Keep Doing Everything That Makes You Feel Better ... Except For This Long List of Things	A. V. Ambardekar; University of Colorado, Aurora, CO.
Caregiver Burden in Advanced Heart Failure: The Forgotten	R. M. Masterson Creber; Healthcare Policy & Research, Weill Cornell Medicine, New York City, NY.
Moderator (Panel / Q&A)	A. S. Laramee; University of Vermont Medical Center, Burlington, VT.
Case Study & Panel Discussion	
<b>2020 and Beyond: Background Medical Therapy for Clinical Trials</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	O. Vardeny; Minneapolis VA Health Care System, Minneapolis, MN.
Basic Necessities	G. Fonarow; University of California, Los Angeles, CA.
New Drugs - Dapagliflozin, Vericiguat, Empagliflozin	C. O'Connor; Inova, Falls Church, VA.
GDMT Score	M. Fiuzat; Durham, NC.
HFpEF - Should There Be A Standard?	S. Solomon; Brigham and Women's Hospital, Boston, MA.
Moderator (Panel / Q&A)	J. R. Teerlink; San Francisco VAMC/UCSF, San Francisco, CA.
Panelist	A. Hernandez; Duke University, Durham, NC.
Panelist	N. Stockbridge; Food and Drug Administration, Bethesda, MD.
Panelist	
Panelist	B. Zuckerman; Food and Drug Administration, Bethesda, MD.
<b>Contemporary Challenges in Heart Transplantation: A New Decade, New Opportunities</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	K. Schlendorf; Vanderbilt University Medical Center, Nashville, TN.
Time for a Tune-up: Let the Pharmacist under the Hood Before You Hit the Road	D. Jennings; Columbia University Medical Center, New York, NY.
Charting the Course: Navigating through the New Allocation System to a Successful Transplant	R. J. Cogswell; Medicine, University of Minnesota, Minneapolis, MN.
Finding the Right Travel Buddy: When Should the Kidney Come Along for the Ride?	B. Trachtenberg; Houston Methodist, Houston, TX.
Check the Tire Pressure! What do to When Your Patient has Pre-transplant Pulmonary Hypertension	A. Guha; Cardiology, Houston Methodist, Houston, TX.
Pumping the Breaks on Bad Antibodies: Contemporary Approaches to Sensitized Heart Transplant Candidates	M. Habal; Columbia University, New York, NY.
Moderator (Panel / Q&A)	L. Peters; Advanced Heart Failure and Cardiac Transplantation, University of Colorado, Boulder, CO.
Case Study & Panel Discussion	
<b>HF Hospitalizations and Transitions of Care: It Takes A Village</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	G. Jackson; Cardiology, Medical University of South Carolina, Charleston, SC.
Inpatient Pathways and Team-Based Care to Improve Post-Discharge Outcomes of Hospitalized Heart Failure Patients	S. Hollenberg; Hackensack Meridian University, Hackensack, NJ.
Smoothing Heart Failure Care Transitions: Contemporary Strategies Utilizing Case Managers and APNs	N. M. Albert; Cleveland Clinic, Cleveland, OH.
Get the Medications Right: Pharmacists Optimizing GDMT During Transitions of Care	V. Groo; University of Illinois at Chicago, Chicago, IL.
Whose Job is it Anyway? Managing Comorbidities Following Heart Failure Discharge	S. M. Joseph; Baylor University Medical Center, Dallas, TX.
The "Other" Transition: When and How to Consider Palliative Care in Patients with Heart Failure	J. Rogers; Duke University Health System, Durham, NC.
Moderator (Panel/ Q&A)	P. Kirkwood; St. Joseph Heritage Healthcare, CA.
Case Study & Panel Discussion	
<b>JNC New Investigator Award: Basic, Translational and Clinical</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	R. C. Starling; Cleveland Clinic, Cleveland, OH.
Validation Of Natriuretic Response Prediction Equation In Patients With Acute Decompensated Heart Failure	Olyvia Gleason; Yale University School of Medicine, New Haven, CT
Circulating Protein Biomarkers Associated With Heart Failure With Preserved Ejection Fraction	Jessica Regan; Duke University, Durham, NC
The Effect Of The Cardiac Myosin Activator, Omecamtiv Mecarbil, On Right Ventricular	Tor Biering-Sørensen; Herlev and Gentofte Hospital, København Ø, Denmark
Race And Sex-specific Population Attributable Fractions For Incident Heart Failure: Lifetime Risk Pooling Project	Arjun Sinha; Northwestern Feinberg School of Medicine; Chicago, IL
A Novel Metabolomics Risk Score Associated With Sex-differences In Heart Failure	Aditi Nayak; Emory University, Atlanta, GA
Reviewer/Judge (Chair)	Jeffrey M. Testani, Yale University, New Haven, CT
Reviewer/Judge	Sheryl L. Chow, Western University of Health Sciences, Pomona, CA

Reviewer/Judge	John Burnett. Mayo Clinic, Rochester, MN
Reviewer/Judge	Muthiah Vaduganathan. Brigham and Women's Hospital Heart and Vascular Ce, Boston, MA
Reviewer/Judge	Jane Wilcox. Northwestern University Feinberg School of Medicine, Chicago, IL
<b>Nurse Investigator Award: Research and Clinical</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator	J. Howie-Esquivel; Charlottesville, VA.
Moderator	M. Callihan; Allegheny Health Network, Pittsburgh, PA.
Enhancing Shared Decision Making In A Chronic Population. Use Of An Advance Directive Decision Aid For Patients With Heart Failure And Their Caregivers.	Emily Benton; University of Colorado Denver, CO
Predictive Model For Risk Of 30-day Rehospitalization Using A Natural Language Processing/machine Learning Approach Among Medicare Patients With Heart Failure	Youjeong Kang; University of Utah, Salt Lake City, UT
Blacks With Hypertrophic Cardiomyopathy Have Lower Quality Of Life And Exercise Capacity Than Whites	Milla Arabadjian; NYU Rory Meyers College of Nursing; New York, NY
Virtual Outpatient Heart Failure Care - Lessons From The Covid-19 Era	Sharon Ugolini; University of Utah Heath Salt Lake City, UT
Reducing Heart Failure Readmissions Through A Shared Medical Appointment	Lisa Filyo; VA, Orlando, FL
Our Experience With Using Watchpat® (itamar Medical, Ltd.), Home Sleep Testing (hst) For The Diagnosis Of Sleep Apnea In Advanced Heart Failure Patients	Sandra Carey; Baylor Scott and White HCS, Colleyville, TX
Reviewer/Judge	W. Alonso; College of Nursing, University of Nebraska Medical Cent, Omaha, NE.
Reveiwer/Judge	Q. E. Denfeld; School of Nursing, Oregon Health & Science University, Portland, OR.
Reviewer/Judge	C. Lewis; Vanderbilt University Medical Center, Nashville, TN.
Reviewer/Judge	J. Bidwell; University of California, Davis, Davis, CA.
Reviewer/Judge	P. E. Brennan; Transplant, Tampa General Hospital, Tampa, FL.
<b>Friday Plenary : Impact of Music in HF - A Live Panel Discussion</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Introductions of Moderators and Panel	B. Bozkurt; Dallas, TX.
Moderator	M. Rich; Washington University, St. Louis, St. Louis, ME.
Beneficial Effects of Listening to Classical Music in Patients with HF: a Randomized Controlled Trial	P. Hauptman; University of Tennessee Knoxville, Knoxville, TN.
Panel	R. Fleming; Soprano Renée Fleming, -, DC.
Panel	E. Edwards; National Center for Complementary & Integrative Health, Bethesda, MD.
Panel	J. Fleg; National Center for Complementary & Integrative Health, Bethesda, MD.
Panel	J. Kulinski; Medical College of Wisconsin, HUB for Collaborative Medicine, Wauwatosa, WI.
Panel	S. Robb; Indiana University School of Nursing, Indianapolis, IN.
<b>2020 ASM - PLE. Healthcare Future 360 (CEUs)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Welcome - ASM Introduction and Dr. Dzau Introduction	B. Bozkurt; Houston, TX.
Distinguished Plenary Lecture - CV Continuum 2020 and Beyond: Emerging Science, Technology, and Innovation	V. Dzau; National Academy of Medicine, Washington, DC.
Introduction of Panelists	J. Butler; 2020 ASM Program Chair, HFSA, Rockville, MD.
Moderator(s)	J. Butler; 2020 ASM Program Chair, HFSA, Rockville, MD.
Moderator(s)	B. Bozkurt; 2020 President, HFSA, Rockville, MD.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	E. Braunwald; Chairman, TIMI Study Group, Professor Harvard Medical School, Brigham and Women's Hospital, Division of Cardiovascular Medicine, Boston, MA.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	N. Brown; Chief Executive Officer, American Heart Association, Dallas, TX.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	H. Krumholz; Yale School of Medicine, New Haven, CT.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	J. Mega; Chief Medical and Scientific Officer, Verily Life Sciences, San Francisco, CA.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	G. Mensah; Center Director , Center for Translational Research and Implementation Science, NHLBI, Bethesda, MD.
Panelist(s) - The Future of Medicine: Science, Technology, Ethics, and Patient Centeredness	A. Poppas; President, American College of Cardiology (ACC); Chief of the Cardiology Division Director of Lifespan Cardiovascular Institute for Rhode Island Miriam, and Newport Hospitals; Professor of Medicine, Brown University, Providence, RI.
<b>President's Address &amp; Lifetime Achievement Awards (No CEUs)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Master of Ceremonies and Introductions	J. Barnes; HFSA CEO, Rockville, MD.
Incoming Presidents Address	N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.
Outgoing President's Address and Introduction of John Burnett	B. Bozkurt; Houston, TX.
Lifetime Achievement Award Acceptance	J. Burnett; Mayo Clinic, Rochester, MN.
Closing Remarks	J. Barnes; HFSA CEO, Rockville, MD.
<b>EMPEROR Reduced</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Primary Results with Emphasis on Major Primary and Secondary Endpoints and Safety	M. Packer; Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX.
Comparison of Effects of Empagliflozin in Patients with HF With and Without Diabetes	S. Anker; Charité Medical School of the Humboldt University Berlin, Germany, Berlin, GERMANY.
Discussant	M. Costanzo; Advocate Heart Institute, Naperville, IL.
Comparison of DAPA-HF and EMPEROR-Reduced	F. Zannad; Hopital Brabois, CIC-P Inserm/CHU, Vandoeuvre-Les-Nancy, FRANCE.
Safety and Clinical Implications	G. Filippatos; University of Athens, Athens, GREECE.
Discussant	S. Greene; Duke University School of Medicine, Durham, NC.
Moderator (Panel / Q&A)	J. Pedro Ferreira; Centre Hospitalier Universitaire de Nancy, Laxou, FRANCE.
Case Study & Panel Discussion	
<b>Management of HF in Rural/Fronteir Areas: Challenges and Potential Solutions for Clinical Practice and Research</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	J. Howie-Esquivel; University of Virginia School of Nursing.
Access to care in rural/frontier settings: Current challenges and potential solutions	W. Alonso; University of Nebraska College of Nursing.
GDMT Implementation in rural/frontier settings: Current challenges and potential solutions	R. Page; University of Colorado.
The importance of health literacy in rural/frontier settings	D. Moser; University of Kentucky College of Nursing.
Clinical Practice Challenges and Needs in Rural/Frontier Settings	L. L. Wick; University of MN, Duluth, MN.
Research Challenges and Needs in Rural/Frontier Settings	L. J. Graven; College of Nursing, Florida State University, Tallahassee, FL.
Moderator (Panel / Q&A)	D. Moser; University of Kentucky, Lexington, KY.
Case Study & Panel Discussion	
<b>Myocarditis: Management Update</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	J. Alexis; University of Rochester Medical Center, Rochester, NY.
2020 AHA Scientific Statement on the Management of Fulminant Myocarditis	J. C. Fang; University of Utah, Salt Lake City, UT.

Cardiac Sarcoidosis: A Not So Rare Cause of Cardiomyopathy	N. Gilotra; Johns Hopkins, Baltimore, MD.
Role of MRI and PET Imaging for the Diagnosis of Acute Myocardial Inflammation	R. Blankstein; Brigham and Women's Hospital, Boston, MA.
Choice of Mechanical Circulatory Support for Fulminant Myocarditis	H. Vidula; University of Rochester, Rochester, NY.
Ongoing Trials for Acute Myocarditis and Sarcoidosis	L. T. Cooper; Mayo Clinic, Jacksonville, FL.
Moderator (Panel /Q&A)	
Case Study & Panel Discussion	
<b>Unfolding Development in the Care of Patients with TTR Cardiac Amyloidosis</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	A. R. Patel; The CardioVascular Center, Tufts Medical Center, Boston, MA.
Understanding Cardiac Amyloidosis: Insights from the Bench	K. Alexander; Stanford University, Stanford, CA.
The Road to Diagnosis: Whom Do I Screen, When Do I Biopsy	B. Sperry; St. Lukes Mid America, Kansas City, MO.
Imaging for Cardiac Amyloidosis: Pearls and Pitfalls	S. Dorbala; Brigham and Womens, Boston, MA.
Advanced Heart Failure Therapies in the Patient with Cardiac Amyloid	J. Grodin; UT Southwestern, Dallas, TX.
Current and Emerging Therapies for Transthyretin Amyloidosis	M. Maurer; Columbia University, New York, NY.
Practical Tips for Pharmacotherapy Challenges in Transthyretin Amyloidosis, Including Helping Patients Navigate Access to Therapy	L. West; Cleveland Clinic, Cleveland, OH.
Moderator (Panel/ Q&A)	M. Hanna; Cardiology, Cleveland Clinic Foundation, Cleveland, OH.
Case Study & Panel Discussion	R. Wittles; Stanford University Medical Center, Stanford, CA.
<b>Dangerous Liaisons in Pulmonary Hypertension</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. A. Simon; University of Pittsburgh, Pittsburgh, PA.
Case 1: Double Trouble	P. Forfia; HFSA, Northfield, MN.
Case 2 - Double, Double, Toil and Trouble	S. Airhart; Providence Heart Institute, Portland, OR.
Case 3: How Unlucky Can You Get	A. Schnell Heringer; University of California - San Francisco, San Francisco, CA.
Panel Discussion and/or Q&A	
Panel Member 1	M. Gomberg-Maitland; George Washington University, Washington, DC.
Panel Member 2	H. Ventura; Ochsner Clinic Foundation, New Orleans, LA.
Panel Member 3	S. Murali; Allegheny Health Network, Pittsburgh, PA.
Panel Member 4	M. Kanwar; Allegheny General Hospital, Pittsburgh, PA.
<b>Structural Interventions for A Falling Heart - A Partnership Between Interventional and HF Cardiologists</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	J. Rosenthal; Mayo Clinic Arizona, Phoenix, AZ.
To Clip or Not to Clip: That Is the Debate! MitraClip Confirmed	J. Lindenfeld; medicine, Vanderbilt University Medical Center, Nashville, TN.
To Clip or Not to Clip: that Is the Debate! MitraClip - Need More Data	M. Acker; University of Pennsylvania, Philadelphia, PA.
Percutaneous Tricuspid Valve Interventions: Myth or Reality	S. F. Bolling; Michigan Medicine University of Michigan, Ann Arbor, MI.
Transcatheter Aortic Valve Replacement for Patients with Low Ejection Fraction: Should It be Used for the Low Flow, Low Gradient State?	M. Reardon; Houston Methodist Hospital, Houston, TX.
Atrial unloading to treat ventricular dysfunction: conceptual framework and therapies	D. Burkhoff; Cardiovascular Research Foundation, New York, NY.
Moderator (Panel/ Q&A)	N. Uriel; Columbia Presbyterian University, New York, NY.
Case Study & Panel Discussion	
<b>Advances in the Treatment of Monogenic Cardiomyopathies</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	E. Adler; UCSD, La Jolla, CA.
Hypertrophic Cardiomyopathy - Out with the Old	J. Tardiff; University of Arizona, Tucson, AZ.
Dilated Cardiomyopathy - Personalizing Common Treatments	K. Sallam; Stanford University, Stanford, CA.
Risk Stratification and Management of Arrhythmogenic Cardiomyopathies	M. Maron; Tufts Medical Center, Boston, MA.
Practical Approaches to Patients Suspected of Genetic Cardiomyopathies	R. Hershberger; Ohio State University, Columbus, OH.
EXPLORER - HCM: What Have We Learned?	A. Masri; Oregon Health & Science University, Portland, OR.
Moderator (Panel / Q&A)	J. Wu; Stanford, CA.
Case Study & Panel Discussion	
<b>Traversing Care and Guidelines for Patients with HF and Multiple Co-Morbidities</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	S. Dunbar; Atlanta, GA.
Evaluation of the Patient with Heart Failure and Multiple Co-Morbidities: A Case Example	M. Walsh; St. Vincent Heart Center, Indianapolis, IN.
Patient Centered Care When Care is Complex: Setting Priorities with the Patient and Family	R. Gary; Emory University, Atlanta, GA.
Juggling and Sequencing Priorities in Patients with Multiple Co-morbidities	G. Levine; Baylor College of Medicine, Houston, TX.
When Do We Turn to Palliative Care Guidelines: Enabling the Patient and Family	A. S. Laramee; University of Vermont Medical Center, Burlington, VT.
Confronting Polypharmacy and Shared Decision-Making in Medication Management with Comorbidities and HF	T. Macaulay; University of Kentucky, Lexington, KY.
Moderator (Panel / Q&A)	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Case Study & Panel Discussion	
<b>Late Breaking Clinical Trials I (LBCT I)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Mehra; Harvard University, Boston, MA.
Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial	Barry A. Borlaug <sup>1</sup> , Daniel Burkhoff <sup>2</sup> , Sanjiv Shah <sup>3</sup> , Ronald Zolty <sup>4</sup> , Ryan Tedford <sup>5</sup> , Thenappan Thenappan <sup>6</sup> , Roham Zamanian <sup>7</sup> , Jeremy Mazurek <sup>8</sup> , Jonathan Rich <sup>3</sup> , Marc Simon <sup>9</sup> , Stuart Rich <sup>3</sup> . <sup>1</sup> Mayo CLinic, Rochester, MN; <sup>2</sup> Columbia University, New York, NY; <sup>3</sup> Northwestern, Chicago, IL; <sup>4</sup> University of Nebraska, Omaha, NE; <sup>5</sup> Medical University of South Carolina, Charleston, SC; <sup>6</sup> University of Minnesota, Minneapolis, MN; <sup>7</sup> Stanford, Stanford Health Care, CA; <sup>8</sup> University of Pennsylvania, Philadelphia, PA; <sup>9</sup> UPMC Heart and Vascular Institute, Pittsburgh, PA
DISCUSSANT - Levosimendan Improves Hemodynamics And Submaximal Exercise Capacity In Ph-hfpef: Primary Results From The Help-ph-hfpef Multicenter Randomized Controlled Trial	K. Sharma; Medicine, Johns Hopkins Hospital, Baltimore, MD.
Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial	Joao Pedro Ferreira. CIC-P Nancy, Vandoeuvre-les-Nancy, France
DISCUSSANT- Mechanistic Insight Into The Effect Of Spironolactone For Preventing Heart Failure: Proteomics And Knowledge-based Network Analysis From The Homage Trial	B. Pitt; cardiology, University of Michigan school of Medicine, Ann Arbor, MI.
Excess 30-Day Heart Failure Readmission In Blacks Increases With Neighborhood Deprivation	Shivani Anil Patel, Kaitlyn Long, Theresa E. Shirey, Neal J. Dickert, Alanna A. Morris. Emory University, Atlanta, GA
DISCUSSANT - Excess 30-Day Heart Failure Readmission In Blacks Increases With Neighborhood Deprivation	K. Ferdinand; Tulane University, New Orleans, LA.
Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)	J. J. McMurray; Institute of Cardiovascular and Medical Sciences-, Glasgow, BC.

DISCUSSANT - Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD)	M. Weir; University of Maryland School of Medicine, Baltimore, MD.
Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials	Stefan D. Anker <sup>1</sup> , Piotr Ponikowski <sup>2</sup> , Christoph Wanner <sup>3</sup> , Egon Pfarr <sup>4</sup> , Sibylle Hauske <sup>4,5</sup> , Barbara Peil <sup>4</sup> , Afshin Salsali <sup>6</sup> , Ivana Ritter <sup>4</sup> , Matias Nordaby <sup>4</sup> , Audrey Koitka-Weber <sup>3,4</sup> , Martina Brueckmann <sup>4</sup> , Waheed Jamal <sup>4</sup> , JoAnn Lindendorf <sup>7</sup> , William T. Abraham <sup>1,8</sup> . 1Charité University, Berlin, Germany; 2Wrocław Medical University, Wrocław, Poland; 3Würzburg University Clinic, Würzburg, Germany; 4Boehringer Ingelheim, Ingelheim, Germany; 5University of Heidelberg, Heidelberg, Germany; 6Boehringer Ingelheim, Ridgefield, CT; 7Vanderbilt University Medical Center, Nashville, TN; 8The Ohio State University, Columbus, OH
DISCUSSANT - Kidney Function After Initiation And Discontinuation Of Empagliflozin (EMPA) In Heart Failure (HF) Patients (Pts) With And Without Type 2 Diabetes (T2D): Insights From The Empirical Trials	S. S. Gottlieb; University of Maryland, Baltimore, MD.
Moderator (Panel / Q&A)	G. Filippatos; University of Athens, Athens, GREECE.
Case Study & Panel Discussion	
<b>Knowing It When You See It: Defining Congestion and Decongestion</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	J. Thibodeau; UT Southwestern, Dallas, TX.
"Wet and Upset" - Why Congestion Is Such a Big Deal In Heart Failure	G. Felker; Duke Clinical Research Institute, Durham, NC.
True, True, and Related - Teasing out the Complex Interrelationship Between Volume Status and Congestion	W. L. Miller; Cardiovascular, Mayo Clinic, Rochester, MN.
The Ups and Downs of Natriuretic Peptides for Detecting Congestion	K. Adams, Jr.; University of North Carolina at Chapel Hill, Chapel Hill, NC.
Patients - You Can't Escape A Visit to the Doctor Just Yet	M. Drazner; UT Southwestern, Dallas, TX.
Trading In My Stethoscope for A Laptop - We Are Better Off Using Devices To Assess Congestion In Our Patients	A. B. Miller; Cardiology, University of Florida- Shands Jacksonville, Jacksonville, FL.
Moderator (LIVE Panel / Q&A)	A. M. Feldman; Temple University, Philadelphia, PA.
Case Study & Panel Discussion	
<b>When Social Determinants Health Collide with HF Care and Treatment Decisions</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	K. A. Sethares; Adult and Child Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA.
Implicit and Explicit Bias In Medical Decision-Making	Q. Capers, IV; Ohio State University Medical Center, Columbus, OH.
Racial/Ethnic Disparities In Transplant and LVAD Candidacy	K. Breathett; University of Arizona, Tucson, AZ.
Gender Disparities In Transplant and LVAD Candidacy	A. A. Morris; Cardiology, Emory University, Atlanta, GA.
Psychosocial Economic Determinants of Advanced Heart failure and Treatment Outcomes: How to Appropriately address and Factor Into Candidacy	K. L. Grady; Northwestern University, Philadelphia, PA.
Advanced Heart Failure Selection Committees: How the Sausage is Made, and How We Can Make It Even Better	P. Khazanie; University of Colorado, Aurora, CO.
Moderator (Panel/Q&A)	L. L. Wick; University of MN, Duluth, MN.
Case Study & Panel Discussion	
<b>New Data and Learnings from VICTORIA Trial</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	P. Armstrong; Canadian VIGOUR Centre, University of Alberta, Edmonton, AB, CANADA.
Defining an Optimal Standard of Background Medical Care : Insights from VICTORIA	J. Ezekowitz; AB, CANADA.
Recurrent Events After Hospitalization for Worsening Heart Failure: New findings from VICTORIA	R. J. Mentz; Duke University Medical Center, Durham, NC.
Discussant	W. C. Levy; Seattle, WA.
Prognostic Modelling in Patients with HFrEF and Recent Decompensation: Insights from VICTORIA	A. F. Hernandez; Durham, NC.
Where Does Vericiguat Fit in the Contemporary Standard of Care Management of HFrEF Care?	J. Butler; University of Mississippi, Jackson, MS.
Discussant	U. Elkayam; University of Southern California, Los Angeles, CA.
Panel Discussion / Q&A	
Moderator (Panel / Q&A)	C. O'Connor; Inova, Falls Church, VA.
<b>International Session - Universal Definition of Heart Failure</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Introduction to Mihai Gheorghiade Lectureship	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Mihai Gheorghiade Lectureship: The Five Alive	J. J. McMurray; University of Glasgow, Glasgow, UNITED KINGDOM.
Introduction to International Session	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Proposed Universal Definition of HF	A. J. Coats; University of Monash, Coventry, UNITED KINGDOM.
Proposed Classifications of HF According to EF	K. Yamamoto; Tottori University, Yonago, JAPAN.
Proposed Stages of HF	B. Bozkurt; Baylor College of Medicine, Houston, TX.
Definitions According to Clinical and EF Trajectory	S. Zieroth; University of Manitoba, Winnipeg, MB, CANADA.
Awarding of Honorary International FHFA Andrew Coats, MD of the United Kingdom Maria Crespo-Liero, MD of Spain Tiny Jaarsma, RN of Sweden John McMurray, MD of Scotland	B. Bozkurt; Houston, TX.
<b>Cardiogenic Shock in 2020: Evolving Definitions, Devices and Delivery</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	S. Hall; Baylor University Medical Center.
Challenges in Defining and Classifying Cardiogenic Shock: Why It is Important to Speak a Unified Language	D. Baran; Sentare Healthcare.
Coming Together: How to Build A Multidisciplinary Shock Team	M. Givertz; Brigham and Women's Hospital, Boston, MA.
The Toolbox of the Shock Team in 2020: Hemodynamic Effects of Acute MCS Devices	N. Uriel; Columbia University Medical Center.
How to Approach Percutaneous MCS for Shock Patients On the Transplant List	U. Jorde; Bronx, NY.
The Modern CICU: A Multidisciplinary Comprehensive Critical Care Unit for the Entire Arc of Heart Failure, Transplant, and MCS	D. Berg; Brigham and Women's Hospital, Boston, MA.
A Challenging Case in Cardiogenic Shock: Focus on Acute MI	E. E. Vorovich; Chicago, IL.
Challenging Cases in Cardiogenic Shock: Focus on Acute on Chronic Heart Failure	A. Garan; Beth Israel Deaconess Medical Center.
Moderator (Panel / Q&A)	J. Fried; Columbia University Medical Center.
Panel Discussion / Q&A	
<b>DAPA-HF: One Year On</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	J. N. Cohn; University of Minnesota, Minneapolis, MN.
DAPA-HF: Additional and Exploratory Clinical Outcomes	M. Kosiborod; Saint Luke's Cardiovascular Consultants, Kansas City, MO.
DAPA-HF: Renal Outcomes	S. Solomon; Brigham and Women's Hospital, Boston, MA.
Discussant	I. Pina; Detroit, MI.
DAPA-HF:Diuretic Therapy	J. J. McMurray; Cardiovascular Research Centre, Glasgow-, UNITED KINGDOM.
DAPA-HF: Other Background Therapy Subgroups	L. Kober; Rigshospitalet University of Copenhagen, Copenhagen, DENMARK.
Discussant	J. G. Cleland; Glasgow, UNITED KINGDOM.
Moderator (Panel / Q&A)	K. Adams, Jr.; University of North Carolina at Chapel Hill, Chapel Hill, NC.

Panel Discussion / Q&A	
<b>Women in HF Career Forum</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	B. Bozkurt; Baylor College of Medicine, Houston, TX.
HFSA & Women in Heart Failure	J. Lindenfeld; Vanderbilt University Medical Center, Nashville, TN.
Keys to Success: Grit, Grace and Definitions	L. Stevenson; Vanderbilt Heart & Lung Institute, Nashville, TN.
Imposter Syndrome: Recognize and Overcome It	M. Ginwalla; Cardiology, Palo Alto Medical Foundation/Sutterhealth, Palo Alto, CA.
Research, Scholarship and the Power of the Pen	R. M. Masterson Creber; Healthcare Policy & Research, Weill Cornell Medicine, New York City, NY.
Dr. Mom's Balancing Act to Juggle the Puzzle & Thrive	I. Pina; Wayne State University, Detroit, MI.
Taking Mentorship One-Step Further	J. E. Rodgers; UNC Eshelman School of Pharmacy, Chapel Hill, NC.
Moderator (Panel / Q&A)	S. Ammon; San Francisco, CA.
Panel Discussion / Q&A	
<b>Cardiac Cachexia: Mechanisms, Measuring Muscle, and Managing Malnutrition</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	L. M. Freeman; Cummings School of Veterinary Medicine, Tufts University, North Grafton, MA.
Moderator (Panel / Q&A)	S. von Haehling; Charite Campus Virchow-Klinikum, Berlin, GERMANY.
Why Should We Take Notice of Skeletal Muscle Wasting in Patients with Heart Failure	A. Coats; Monash University, Melbourne, AUSTRALIA.
Defining Cardiac Cachexia: How Do We Develop Therapies for A Condition Without Diagnostic Criteria	S. Anker; Charite Campus Virchow-Klinikum, Berlin, GERMANY.
Molecular Mechanisms and Promising Pharmacological Therapies for Patients with Cardiac Cachexia	A. Vest; Tufts Medical Center, Boston, MA.
Overlap of Cardiac Cachexia and Cancer Cachexia	M. S. Anker; Charité – Universitätsmedizin Berlin, Berlin, GERMANY.
Does Malnutrition Drive Cardiac Cachexia?	L. Parsly; Frances Stern Nutrition Center, Tufts Medical Center, Boston, MA.
Panel Discussion / Q&A	
<b>Targeting Therapy for HFpEF</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	A. Kalogeropoulos; Medicine (Cardiology), Stony Brook University, Stony Brook, NY.
Scores and More: Diagnostic Approaches for HFpEF	A. S. Desai; Heart and Vascular Center, Brigham and Women's Hospital, Boston, MA.
Back to the Basics: Can Animal Models of HFpEF Better Guide Therapeutic Strategies?	J. Hill; Ut Southwestern, Dallas, TX.
Machine Learning to Guide Therapeutic Strategic in HFpEF: Fact or Fiction?	T. Ahmad; Yale School of Medicine, New Haven, CT.
What Have We Learned from Clinical Trials of Medical Therapy in HFpEF: The Path Forward	S. Shah; Northwestern University, Feinberg School of Medicine, Chicago, IL.
Interventional Strategies to Treat HFpEF: Are They Going to Solve the Problem?	M. Fudim; Duke University, Durham, NC.
Moderator (Panel / Q&A)	P. E. Carson; Washington VAMC, Washington DC, DC.
Panel Discussion / Q&A	
<b>Remote Monitoring for HF - Specialized Devices and ICDs (No CEUs)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Introduction- COVID-19 Implications for Heart Failure Population	K. Breathett; University of Arizona, Tucson, AZ.
Innovation With Remote Heart Failure Monitoring Of The Past, Present, And Future	W. T. Abraham; Division of Cardiovascular Medicine, Ohio State University, Columbus, OH.
Case 1 - Remote Monitoring During COVID-19 - Ambulatory Pulmonary Artery Pressure Monitoring	S. Mazimba; University of Virginia, Charlottesville, VA.
Case 1 - Remote Monitoring During COVID-19 - Ambulatory Pulmonary Artery Pressure Monitoring	C. T. Williams; Henry Ford Hospital, Detroit, MI.
Case 2 - Remote Monitoring During COVID-19 - Electronic remote monitoring interfaces for VAD	A. J. Hicks, III; Baylor Scott & White, Round Rock, TX.
Case 2 - Remote Monitoring During COVID-19 - Electronic remote monitoring interfaces for VAD	L. Klein; UCSF, San Francisco, CA.
Case 3 - Remote Monitoring During COVID-19 - Intrathoracic impedance monitoring	K. Flint; University of Colorado, Denver, CO.
Case 3 - Remote Monitoring During COVID-19 - Intrathoracic impedance monitoring	S. Hall; Baylor Scott & White Advanced Heart Failure Clinic, Dallas, TX.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	S. Zalawadiya; Vanderbilt University, Nashville, TN.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	A. J. Sauer; University of Kansas, Fairway, KS.
Case 4 - Remote Monitoring During COVID-19 -Remote cardiac examination	D. Lanfear; Henry Ford Hospital, Detroit, MI.
Discussant - Wrap Up	K. Breathett; University of Arizona, Tucson, AZ.
Panelist	M. Psotka; Inova Heart and Vascular Institute, Falls Church, VA.
Panelist	T. Alexy; Emory University, Atlanta, GA.
Panelist	M. Ginwalla; Sutterhealth/Palo Alto Medical Foundation, Palo Alto, CA.
Panelist (Medtronic)	S. Sarkar; Medtronic, Minneapolis, MN.
Panelist (Ekos)	L. Le; Ekos, Charlotte, NC.
<b>Women and Gender Influences in Heart Failure</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Mogos; Vanderbilt University School of Nursing, Nashville, TN.
Women and Gender Influences in Heart Failure	J. E. Ho; Massachusetts General Hospital, Boston, MA.
Sex Differences in Chemotherapy-Induced Cardiomyopathy	M. Bloom; Stony Brooke University, New York, NY.
Are There Sex Differences in Heart Failure Treatments: Medications, Mechanical Circulatory Support and Transplantation	E. M. DeFilippis; Columbia University Irving Medical Center, New York, NY.
Heart Failure Treatment in Women: Exercise and Cognitive Behavior Therapy - What Works?	R. Gary; Emory University, Atlanta, GA.
Heart Failure Across the Pregnancy Continuum: A Rising Concern	J. Briller; University of Illinois, Chicago, IL.
Moderator (Panel / Q&A)	S. Mohammed; Medstar Heart and Vascular Institute, Washington, DC.
Panel Discussion / Q&A	
<b>Understanding Heart Failure with Recovered Ejection Fraction</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	E. Shao; Tufts University, Maine Medical Center, South Portland, ME.
Recovering Cardiac Function After Injury: Lessons from the Laboratory	W. Koch; Temple University, Philadelphia, PA.
Resynchronization Super-Responders: Who, Why and What Next?	R. Kahwash; Columbus, OH.
Prioritizing Polypharmacy in Recovered Ejection Fraction	J. Wilcox; Medicine-Cardiology, Northwestern University Feinberg School of Medicine, Chicago, IL.
Recovering Ejection Fraction After Viral Myocarditis, Who, Why, and What Are We Going Learning from COVID-19?	S. Pinney; University of Chicago, Chicago, IL.
Moderator (Panel/Q&A)	K. B. Margulies; University of Pennsylvania School of Medicine, Philadelphia, PA.
Panel Discussion/Q&A	
<b>Integrated Omics in Heart Failure: Precision Medicine Highlights for HF Clinicians and Scientists</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Piano; Vanderbilt University, Nashville, TN.
To Screen or Not to Screen: Approach to Clinical Genetic Testing in Patients with Heart Failure	A. Owens; University of Pennsylvania, Philadelphia, PA.
Proteomics: From Discovery to Validated Biomarkers	M. Naylor; Massachusetts General Hospital, Boston, MA.

Understanding the Role of the Gut Microbiome in Heart Failure	W. Tang; Cleveland Clinic, Cleveland, OH.
Pharmacogenomics: Are We Ready for Prime Time?	D. Lanfear; Henry Ford Hospital, Detroit, MI.
The Case for Diversity to Enhance the Impact of Precision Medicine Research	L. Hindorff; National Human Genome Research Institute, Bethesda, MD.
Moderator (Panel / Q&A)	J. Luzum; University of Michigan, Ann Arbor, MI.
Panel Discussion/Q&A	
<b>The Intersection of Cardio-Oncology and Advanced Heart Failure: From Stage A to D</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	D. Lenihan; Washington School of Medicine at St. Louis, St. Louis, MO.
Building a Successful Cardio-Oncology Program 101	J. Durand; MD Anderson Cancer Center, Houston, TX.
Screening for Cardiotoxicity; Imaging? Biomarkers? or None at All	J. Liu; Memorial Sloan Kettering Cancer Center, Manhattan, NY.
What's Old, New and Emerging About Cardiotoxicity?	A. Barac; Medstar Washington Hospital Center, Washington DC, DC.
Immunotherapy and Cardiac Dysfunction: From Mechanisms to Therapy	J. Moslehi; Vanderbilt University Medical Center, Nashville, MS.
Advanced Cardio-oncology: What About LVAD and Heart Transplant Patients?	J. Raikhelkar; Columbia University Medical Center, New York, NY.
Moderator (Panel Q&A)	A. Nohria; Brigham and Women's Hospital, Boston, MA.
Panel Discussion/Q&A	
<b>Atrial Fibrillation and Heart Failure: The Beat Goes On</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	S. Zieroth; University of Manitoba, Winnipeg, MB, CANADA.
Cardiomyopathy or Atrial Myopathy: Understanding Pathophysiology	A. Ducharme; Medicine, Montreal Heart Institute, Montreal, QC, CANADA.
Comparing and Contrasting the US and Canadian Guidelines (Rate/Rhythm/Ablation)	J. Andrade; Vancouver Coastal Health, Vancouver, BC, CANADA.
HFpEF and Atrial Fibrillation as a Phenotype	K. Sharma; Medicine, Johns Hopkins Hospital, Baltimore, MD.
Moderator (Panel with Q&A)	
Panelist	C. Albert; Cedars Sinai, Los Angeles, CA.
Panel Discussion	
<b>Implementation: Systematic Strategies of Improving Care and Outcomes</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	N. M. Albert; Nursing Institute-Research and Innovation, Cleveland Clinic, Cleveland, OH.
Overcoming Clinical Inertia in Use and Dosing of GDMT	S. Greene; Duke University School of Medicine, Durham, NC.
How to Get SGLT2 Inhibitors and Other New Therapies Into Clinical Use	O. Vardeny; Minneapolis VA Health Care System, Minneapolis, MN.
Implementing Patient Reported Outcome Measures in Clinical Practice	J. Spertus; University of Missouri - Kansas City, Kansas City, MO.
Health Care Policies that Could Incentivize Implementation in HF	K. Joynt Maddox; Washington University, St. Louis, MO.
Moderator (Panel / Q&A)	G. Fonarow; University of California, Los Angeles, CA.
Panel Discussion / Q&A	
<b>Clinical-Pathological Cases (CPC): Stump the Professor</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator	M. Drazner; UT Southwestern, Dallas, TX.
Case 1	A. Lala; Mount Sinai, New York, NY.
Case 2	M. Nassif; Saint Lukes Mid America Heart Institute, Kansas City, MO.
PROFESSOR Panelist	B. Greenberg; University California San Diego, La Jolla, CA.
PROFESSOR Panelist	M. Konstam; Tufts Medical Center, Boston, MA.
PROFESSOR Panelist	M. Mehra; Brigham and Women's Hospital / Harvard University, Boston, MA.
<b>Patient Pearls for Advanced Heart Failure: A View from the Other Side</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	S. E. Schroeder; Bryan Heart, Lincoln, NE.
What is High Value Care?	L. Allen; University of Colorado School of Medicine, Denver, CO.
Tomorrow Belongs to Those Who Prepare for It Today: Leaning Into Advanced Heart Failure	A. Anderson; UT Health San Antonio, San Antonio, TX.
You Want to Do What to Me? Preparing for Cardiac Procedures	M. Bloom; Stony Brooke University, New York, NY.
It Is A Team Sport: The Joys and Challenges of Family Caregiving	T. Jaarsma; Linkoping University, Linkoping, SWEDEN.
Patient Panelist	C. Chauhan; Patient Advocate, Wichita, KS.
Patient Panelist	R. Monroe; None, Washington, DC.
Moderator (Panel/Q&A)	S. Gale; University of Maryland School of Pharmacy, Baltimore, MD.
Panel Discussion / Q&A (with Patients and Session Faculty)	
<b>Late Breaking Clinical Trials II (LBCT II)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	P. Liu; University of Ottawa Heart Institute, Ottawa, ON, CANADA.
Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial	Michael E. Nassif <sup>1</sup> , Mohammed Qintar <sup>1</sup> , Sheryl L. Windsor <sup>1</sup> , Rita Jermyn <sup>2</sup> , David M. Shavelle <sup>3</sup> , Fengming Tang <sup>1</sup> , Sumant Lamba <sup>4</sup> , Kunjan Bhatt <sup>5</sup> , John Brush <sup>6</sup> , Andrew B. Civitello <sup>7</sup> , Robert A. Gordon <sup>8</sup> , Orvar Jonsson <sup>9</sup> , Brent C. Lampert <sup>10</sup> , Jamie Pelzel <sup>11</sup> , Mikhail Kosiborod <sup>1</sup> . <sup>1</sup> Saint Luke's Mid America Heart Institute, Kansas City, MO; <sup>2</sup> St. Francis Hospital, New York, NY; <sup>3</sup> University of Southern California, Los Angeles, CA; <sup>4</sup> First Coast Cardiovascular Institute, Jacksonville, FL; <sup>5</sup> Austin Heart, Austin, TX; <sup>6</sup> Sentara Healthcare, Norfolk, VA; <sup>7</sup> Baylor College of Medicine, Houston, TX; <sup>8</sup> NorthShore University HealthSystem, Evanston, IL; <sup>9</sup> University of South Dakota Sanford Health, Sioux Falls, SD; <sup>10</sup> Ohio State University, Columbus, OH; <sup>11</sup> CentraCare Heart and Vascular Center, St. Cloud, MN
Discussant - Main Results Of The Empagliflozin Evaluation By Measuring Impact On Hemodynamics In Patients With Heart Failure Trial	L. Stevenson; Vanderbilt University, Nashville, TN.
Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy	Justin Ezekowitz <sup>1</sup> , Ciaran McMullan <sup>2</sup> , Cynthia Westerhout <sup>1</sup> , Ileana L. Pina <sup>3</sup> , Jose Lopez-Sendon <sup>4</sup> , Kevin J. Anstrom <sup>5</sup> , Adrian F. Hernandez <sup>5</sup> , Carolyn S. P. Lam <sup>6</sup> , Christopher M. O'Connor <sup>7</sup> , Burkert Pieske <sup>8</sup> , Piotr Ponikowski <sup>9</sup> , Lothar Roessig <sup>10</sup> , Adriaan A. Voors <sup>11</sup> , Joerg Koglin <sup>2</sup> , Paul W. Armstrong <sup>1</sup> , Javed Butler <sup>12</sup> . <sup>1</sup> CVC, U Alberta, Edmonton, AB, Canada; <sup>2</sup> Merck, Kenilworth, NJ; <sup>3</sup> Wayne State U, Detroit, MI; <sup>4</sup> U Hosp La Paz, Madrid, Spain; <sup>5</sup> DCRI, Durham, NC; <sup>6</sup> Natl Heart Ctr, Singapore, Singapore; <sup>7</sup> Inova, Falls Church, VA; <sup>8</sup> Charité U Med, Berlin, Germany; <sup>9</sup> Wroclaw Med U, Wroclaw, Poland; <sup>10</sup> Bayer, Wuppertal, Germany; <sup>11</sup> U Groningen, Groningen, Netherlands; <sup>12</sup> U Mississippi, Jackson, MS
DISCUSSANT - Effect Of Vericiguat In Victoria According To Guideline-directed Medical Therapy	J. Januzzi; Massachusetts General Hospital, Boston, MA.
A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction	Kieran F. Docherty <sup>1</sup> , Ross T. Campbell <sup>1,2</sup> , Katrina J. M. Brooksbank <sup>1</sup> , Rosemary L. Godeseth <sup>1</sup> , Paul Forsyth <sup>3</sup> , Alex McConnachie <sup>4</sup> , Giles Roditi <sup>1,5</sup> , Bethany Stanley <sup>4</sup> , Paul Welsh <sup>1</sup> , Pardeep S. Jhund <sup>1</sup> , Mark C. Petrie <sup>1</sup> , John J. V. McMurray <sup>1</sup> . <sup>1</sup> Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, United Kingdom; <sup>2</sup> Queen Elizabeth University Hospital, Glasgow, United Kingdom; <sup>3</sup> Pharmacy Services, NHS Greater Glasgow & Clyde, Glasgow, United Kingdom; <sup>4</sup> Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom; <sup>5</sup> Glasgow Royal Infirmary, Glasgow, United Kingdom
DISCUSSANT - A Randomized Trial Comparing The Effect Of Sacubitril/Valsartan To Valsartan On Left Ventricular Remodeling In Patients With Asymptomatic Left Ventricular Systolic Dysfunction After Myocardial Infarction	J. Udelson; Tufts Medical Center, Boston, MA.

Endovascular Ablation Of The Right Greater Splanchnic Nerve For The Treatment Of Heart Failure With Preserved Ejection Fraction - First-in-human Clinical Trial	Sanjiv J. Shah <sup>1</sup> , Teona Zirakashvili <sup>2</sup> , Nikoloz Shaburishvili <sup>2</sup> , Giorgi Shaishmelashvili <sup>2</sup> , Horst Sievert <sup>3</sup> , Kolja Sievert <sup>3</sup> , Anisha Bapna <sup>4</sup> , Zoar J. Engelman <sup>4</sup> , Daniel Burkhoff <sup>5</sup> , Tamaz Shaburishvili <sup>2</sup> . 1Northwestern University Feinberg School of Medicine, Chicago, IL; 2Tbilisi Heart and Vascular Clinic, Tbilisi, Georgia; 3Cardiovascular Center Frankfurt, Sankt Katharinen, Frankfurt, Germany; 4Axon Therapies, New York City, NY; 5Cardiovascular Research Foundation, New York City, NY
DISCUSSANT - Endovascular Ablation Of The Right Greater Splanchnic Nerve For The Treatment Of Heart Failure With Preserved Ejection Fraction - First-in-human Clinical Trial	M. Redfield; Mayo Foundation, Rochester, MN.
Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/valsartan	Milton Packer <sup>1,2</sup> . 1Baylor University Medical Center, Dallas, TX; 2Imperial College, London, United Kingdom
DISCUSSANT - Effect Of Empagliflozin On Major Heart Failure Outcomes, Renal Function And Quality Of Life In Patients With Heart Failure With A Reduced Ejection Fraction, With And Without Sacubitril/valsartan	B. L. Claggett; Brigham and Women's Hospital, Boston, MA.
Moderator (Panel / Q&A)	G. Felker; Duke Clinical Research Institute, Durham, NC.
Panel Discussion / Q&A	
<b>Navigating the Early Career Waters: Pearls for Achieving Success - What They Didn't Teach You in Training</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	B. Van Tassell; Virginia Commonwealth University, Richmond, VA.
Early Career Challenges in a Research-Intensive Position	Q. E. Denfeld; Oregon Health & Science University, Portland, OR.
Early Career Challenges in a Clinically-Focused Position at an Academic Medical Center	A. Bhimaraj; Houston Methodist hospital, Houston, TX.
Early Career Challenges in a Position Outside Academia (Research and Clinical)	P. A. Patel; Atrium Health, Concord, NC.
Work-Life Challenges	L. Rose-Jones; University of North Carolina, Chapel Hill, NC.
Lessons Learned	S. Wingate; National Institute of Nursing Research, Bethesda, MD.
Lessons Learned	T. Lennie; University of Kentucky College of Nursing, Lexington, KY.
Moderator (Panel Q&A)	S. Greene; Duke University School of Medicine, Durham, NC.
Case Study & Panel Discussion	
<b>Paper of the Year from Top HF Journals</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Rich; Washington University, St. Louis, MO.
Paper of the Year - Journal of Cardiac Failure (JCF)	M. Rich; St. Louis, MO.
Paper of the Year - JACC-HF	C. O'Connor; Inova, Falls Church, VA.
Best Paper of the Year - Journal of Heart and Lung Transplant (JHLT)	M. Mehra; Brigham and Women's Hospital / Harvard Medical School, Boston, MA.
Paper of the Year - Circulation: HF (Circ-HF)	N. Sweitzer; Arizona EDU, Arizona, AZ.
Paper of the Year - European Journal of HF (EJHF)	M. Metra; University of Brescia, Brescia, ITALY.
Moderator (Live Panel Q&A)	T. M. Ng; School of Pharmacy, University of Southern California, Los Angeles, CA.
Panel Discussion with Q&A	
<b>Management of the Medically Complex Patient (No CEUs)</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Welcomes and Introductions	
Case 1 - Diuretic Resistance - Choose Your Own Adventure Format	B. Moyer; Duke, Durham, NC.
Case 2 - Peripartum Cardiomyopathy - Choose Your Own Adventure Format	K. Faulkenberg; Cleveland Clinic, Cleveland, OH.
Case 3 - Optimization of Heart Failure Therapies in Patients Hospitalized for Non-Cardiovascular Conditions- Choose your Own Adventure Format	L. Buckley; Brigham and Women's Hospital/Harvard Medical School, Boston, MA.
Speaker / Panelist	A. S. Laramée; University of Vermont Medical Center, Burlington, VT.
Speaker / Panelist	J. E. Rodgers; UNC Eshelman School of Pharmacy, Chapel Hill, NC.
Speaker / Panelist	C. Chauhan; Patient Advocate, Wichita, KS.
Speaker / Panelist	N. Ibrahim; Cardiology, Massachusetts General Hospital, Boston, MA.
Speaker / Panelist	M. Psotka; Inova Heart and Vascular Institute, Falls Church, VA.
Closing Remarks	
<b>The Economics of Heart Failure -- Exploring Social Determinants and Financial Burden in the Care of Patients with HF</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	K. D. DiPalo; Montefiore Medical Center, Bronx, NY.
Financial Toxicity - What Is It and What Are the Implications?	K. Nasir; Houston Methodist, Houston, TX.
Assessment of Financial Burden and Its Impact on Health Outcomes	S. D. Slavin; Medicine, Brigham and Women's Hospital, Boston, MA.
Intersection of Financial Burden with Health Disparities	C. W. Yancy; Northwestern University, Chicago, IL.
The Economics of Advanced Therapies	L. Davis; University of North Carolina, Chapel Hill, NC.
Interventions and Policy Innovation to Address Social Determinants of Health and Financial Burden	P. Heidenreich; Stanford VA Palo Alto Medical Center, Palo Alto, CA.
Moderator (Panel / Q&A)	N. Sweitzer; University of Arizona, Tucson, AZ.
Panel Discussion / Q&A	
<b>Dr. Alexa is In: Leveraging Technology in Heart Failure Care</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	K. A. Sethares; Adult and Child Nursing, University of Massachusetts Dartmouth, North Dartmouth, MA.
The Future of Wearables in Patients with Heart Failure	A. D. DeVore; Duke University Medical Center, Durham, NC.
Always Watching: Remote Monitoring	M. Fraser; University of Minnesota, Minneapolis, MN.
Are Virtual Visits the New Reality?	E. Gorodeski; Case Western Reserve University, Cleveland, OH.
Beyond the After-Visit Summary to Educate and Engage Patients	E. Kellison; CHI Franciscan Health, Tacoma, WA.
Information Dissemination in the Era of Facebook and Twitter	M. Kittleson; Cedars-Sinai California Heart Center, Beverly Hills, CA.
Moderator (Panel / Q&A)	C. McIlvennan; University of Colorado, Boulder, CO.
Panel Discussion / Q&A	Faculty
<b>TEACH Workshop</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator	D. Burkhoff; West Harrison, NY.
<b>Research Network Update</b>	
<b>Presentation</b>	<b>Speaker(s)</b>
Moderator (Introductions)	M. Fiuzat; Duke, Durham, NC.
HF Collaboratory / HFSA Joint Site Base Research Awards	C. O'Connor; Inova, Falls Church, VA.
Trial Conduct in the Era of COVID-19 and Beyond - Industry Trial	F. I. Malik; Cytokinetics, San Francisco, CA.
Trial Conduct in the Era of COVID-19 and Beyond - NIH Trial (LOFT)	W. T. Abraham; The Ohio State University Wexner Medical Center, Columbus, OH.
Best Practices During COVID-19: Remote Monitoring and End Points	C. O'Connor; Inova, Falls Church, VA.
Case Study & Panel Discussion	